Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CT-P16 vs Avastin in Healthy Males
NCT03247673Phase 1Completed
- Sponsor
- Celltrion
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 3 more (3 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at 2352 hours, Maximum Serum Concentration at 2352 hours and 1 more. Started Aug 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03247673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247673.